Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
et al., 2020, Acute effects of glucagon on reproductive hormone secretion in healthy men, Journal of Clinical Endocrinology and Metabolism, Vol:105, ISSN:0021-972X
Alexiadou K, Tan TM-M, 2020, Gastrointestinal Peptides as Therapeutic Targets to Mitigate Obesity and Metabolic Syndrome, Current Diabetes Reports, Vol:20, ISSN:1534-4827
et al., 2020, Candy cane revision after Roux-en-Y gastric bypass, Surgical Endoscopy, Vol:34, ISSN:0930-2794, Pages:2076-2081
et al., 2020, The influence of peptide context on signaling and trafficking of glucagon-like peptide-1 receptor biased agonists, Acs Pharmacology & Translational Science, Vol:3, ISSN:2575-9108, Pages:345-360
et al., 2020, Long versus standard biliopancreatic limb in the Roux-en-Y gastric bypass. The LONG LIMB Trial., 11th Annual Scientific Meeting of the British-Obesity-and-Metabolic-Surgery-Society (BOMSS), SPRINGER, Pages:S4-S4, ISSN:0960-8923